Stock listing

NASDAQ:EWTX Edgewise Therapeutics, Inc. Stock

Home listing (NASDAQ) of Edgewise Therapeutics, Inc.

Follow Edgewise Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:EWTX

$39.91 USD -1.46 (-3.5%)

Close on Nov 20, 2026

Past year +79.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$39.71 – $41.40 USDNov 20, 2026
Volume
1.19M sharesNov 20, 2026
Market cap
$4.37B USDAt the close on Nov 20, 2026 · price × 109.5M shares outstanding
52-week range
$19.76 – $48.78 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$63.11M USDMedian day 1.34M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Edgewise Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:EWTX · Home$39.91 USD-1.465 (-3.5%)1,186,702$40.81$41.40$39.71$41.37Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EWTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$39.91-1.465-3.5%$40.81$41.40$39.711,186,702
$41.37-0.67-1.6%$41.95$42.37$40.33866,828
$42.04-1.64-3.8%$43.00$43.95$41.431,401,210
$43.68-2.25-4.9%$45.48$46.00$43.431,279,798
$45.93+0.11+0.2%$45.72$46.75$44.081,162,438
$45.82-1.75-3.7%$46.46$46.93$45.071,097,354
$47.57+1.04+2.2%$46.28$47.85$45.621,343,158
$46.53-2.21-4.5%$46.82$47.79$44.791,939,581
$48.74+3.70+8.2%$45.94$48.78$44.582,466,519
$45.04+6.17+15.9%$39.71$45.76$38.053,608,213
$38.87+1.34+3.6%$43.00$43.25$36.725,041,184
$37.53-0.15-0.4%$38.96$39.48$37.391,030,868
$37.68-0.43-1.1%$38.73$40.41$36.701,859,204
$38.11-0.79-2.0%$38.93$39.71$37.461,083,615
$38.90-0.010.0%$38.72$39.44$38.02967,477
$38.91-1.58-3.9%$40.59$41.60$38.641,209,604
$40.49+0.96+2.4%$39.53$40.56$38.961,629,145
$39.53+0.36+0.9%$39.51$40.33$39.03691,740
$39.17-0.14-0.4%$39.49$40.44$38.701,009,168
$39.31-0.68-1.7%$39.91$39.91$38.91911,110
$39.99+0.34+0.9%$39.11$40.69$38.361,337,725
$39.65-0.10-0.3%$39.95$40.78$39.451,828,373
$39.75+1.83+4.8%$38.03$40.32$37.882,171,190
$37.92+0.73+2.0%$37.41$38.25$36.541,421,580
$37.19-1.01-2.6%$38.28$38.28$36.701,305,500
$38.20+1.18+3.2%$37.62$38.53$37.241,837,400
$37.02+0.74+2.0%$35.93$37.94$35.631,446,100
$36.28-2.17-5.6%$38.17$38.35$36.08810,100
$38.45-0.61-1.6%$39.12$39.36$38.321,536,600
$39.06-0.17-0.4%$39.30$40.41$38.931,062,700
$39.23-0.34-0.9%$38.14$39.41$37.241,363,500
$39.57-0.45-1.1%$39.66$41.06$39.401,446,000
$40.02-0.28-0.7%$40.66$41.03$39.341,624,900
$40.30-1.10-2.7%$41.55$41.79$39.981,633,800
$41.40+0.92+2.3%$41.01$41.94$40.421,459,600
$40.48-0.12-0.3%$40.39$41.46$39.861,286,700
$40.60+1.41+3.6%$39.49$42.12$38.891,678,300
$39.19-0.60-1.5%$39.53$39.58$38.511,920,000
$39.79+0.45+1.1%$39.12$40.10$39.122,983,900
$39.34-1.82-4.4%$41.59$41.99$38.572,487,500
$41.16+0.11+0.3%$40.28$41.94$39.741,378,700
$41.05-3.46-7.8%$44.41$44.41$39.822,607,000
$44.51-0.13-0.3%$44.99$45.99$44.392,091,200
$44.64-0.68-1.5%$45.70$45.98$44.091,178,400
$45.32-1.62-3.5%$46.79$46.93$45.321,991,800
$46.94+1.50+3.3%$46.51$48.51$45.512,407,800
$45.44+1.81+4.1%$43.37$45.60$43.371,683,800
$43.63-0.99-2.2%$44.69$45.02$42.612,969,600
$44.62+0.22+0.5%$43.98$45.70$43.951,104,400
$44.40+1.50+3.5%$43.54$44.80$42.901,404,300
$42.90-0.49-1.1%$42.82$43.50$42.35788,600
$43.39-0.43-1.0%$43.03$44.30$42.97707,700
$43.82+0.75+1.7%$42.85$44.92$42.211,286,400
$43.07+1.12+2.7%$41.73$43.38$41.60826,700
$41.95-0.03-0.1%$42.32$43.00$41.40976,800
$41.98-0.27-0.6%$42.61$43.94$40.761,003,500
$42.25+0.48+1.1%$41.59$42.64$40.821,040,500
$41.77-0.99-2.3%$42.24$42.46$40.641,085,800
$42.76-1.43-3.2%$43.84$44.19$42.72739,800
$44.19-0.19-0.4%$44.16$44.75$43.63995,600
$44.38+0.17+0.4%$44.21$45.05$42.91814,100
$44.21-0.51-1.1%$45.22$46.32$44.021,149,200
$44.72+0.54+1.2%$43.67$45.44$42.591,042,000
$44.18+0.89+2.1%$43.54$44.68$43.001,249,600
$43.29-3.15-6.8%$45.91$45.91$43.081,338,600
Ticker
NASDAQ:EWTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Correction: Edgewise Therapeutics

Nov 9, 2026

Closed $48.74 (+8.2%) on Nov 9, 2026

All Edgewise Therapeutics, Inc. news

Edgewise Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 125 in all · newest Nov 9, 2026 · oldest 2021
Decks
23 decks · latest November 2026

Where Edgewise Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:EWTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:EWTXBOATSUnited StatesUSD

Valuation

P/E 4.3× against a median of 24.5×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.63B USD
P/E
4.3×
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.12

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Edgewise Therapeutics, Inc. · NASDAQ:EWTXUS$4.37BUS$2.63B4.3×n/an/a2.7×n/a0.0×1.12
Liquidia Corporation · NASDAQ:LQDAUS$4.90BUS$4.68Bn/a7.5×n/an/a−15.2%n/a0.84
Erasca, Inc. · NASDAQ:ERASUS$4.78BUS$4.18Bn/an/an/a5.2×n/a0.1×1.51
Dianthus Therapeutics, Inc. · NASDAQ:DNTHUS$4.76BUS$3.92Bn/a1,444×n/a3.8×n/a0.0×0.90
PTC Therapeutics, Inc. · NASDAQ:PTCTUS$4.71BUS$3.12Bn/a2.7×n/an/a−9.2%n/a0.88
Cogent Biosciences, Inc. · NASDAQ:COGTUS$4.65BUS$4.08Bn/an/an/a9.0×n/a0.4×1.30
Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSAUS$4.53BUS$3.97B41.4×4.2×29.9×6.4×11.6%0.0×0.57
Travere Therapeutics, Inc. · NASDAQ:TVTXUS$4.51BUS$4.21Bn/a6.5×n/a200×−18.7%0.0×1.31
Ionis Pharmaceuticals, Inc. · NASDAQ:IONSUS$4.43BUS$4.70Bn/a4.9×n/a11.3×−56.9%5.5×0.40
Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A · SSE:688192US$3.90BUS$3.18B7.5×4.3×n/a5.2×69.3%0.1×n/a
Definium Therapeutics, Inc. · NASDAQ:DFTXUS$3.88BUS$2.87Bn/an/an/a4.0×n/a0.0×1.14
Median of the othersUS$4.59BUS$4.02B24.5×4.9×29.9×5.8×−12.2%0.1×0.90

Forecasts

9 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
55.42 USD · Analysts' mean
EPS, year to Dec 2026
7.83 · 9 analysts

Team and board

Officers

OfficerRole
Michael NofiChief Financial Officer
Behrad DerakhshanChief Operating Officer
John MooreGeneral Counsel
Alan RussellDirector and Co-Founder
Badreddin EdrisDirector and Co-Founder
Joanne M. DonovanChief Medical Officer
Peter ThompsonChairman and Co-Founder

Board

DirectorRole
Peter ThompsonChairman and Co-Founder
Alan RussellDirector and Co-Founder
Arlene MorrisDirector
Badreddin EdrisDirector and Co-Founder
Christopher MartinDirector
Jon RootDirector
Jonathan C. FoxDirector
Kevin KochDirector
Laura BregeDirector

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close+3.6%
Q2 2026Aug 6, 2026 · Before open−1.3%
Q1 2026May 7, 2026 · Before open−3.8%
Q4 2025Feb 26, 2026+1.1%
Q3 2025Nov 6, 2025 · Before open−1.6%
Q2 2025Aug 7, 2025 · Before open−4.2%
Q1 2025May 8, 2025 · Before open+1.2%
Q4 2024Feb 20, 2025 · Before open+1.6%
Q3 2024Nov 7, 2024 · Before open−3.3%
Q2 2024Aug 8, 2024 · Before open+1.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−4.3%
Q4 2023Feb 22, 2024 · Before open−0.7%
Q3 2023Nov 9, 2023 · Before open−7.3%
Q2 2023Aug 10, 2023 · Before open+3.9%
Q1 2023May 11, 2023 · Before open−4.0%
Q4 2022Feb 23, 2023 · Before open−2.0%
Q3 2022Nov 3, 2022 · Before open+6.8%
Q2 2022Aug 4, 2022 · Before open+10.3%
Q1 2022May 11, 2022 · Before open−3.8%
Q4 2021Feb 24, 2022 · Before open+4.6%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2026)Technical9 slidesNovember 2026
Technical Presentation (October 2026)Technical6 slidesOctober 2026
Technical Presentation (September 2026)Technical42 slidesSep 22, 2026
Technical Presentation (August 2026)Technical25 slidesAugust 2026
World Muscle Society Conference 2025 SymposiumConference55 slidesOct 8, 2025
Technical Presentation (April 2025)Technical50 slidesApr 2, 2025
Technical Presentation (December 2024)Technical38 slidesDec 16, 2024
Technical Presentation (December 2024)Technical37 slidesDec 16, 2024
Investor Presentation (November 2024)Investor deck57 slidesNovember 2024
Corporate Update (September 2024)Corporate update43 slidesSep 19, 2024
All 23 decks
DeckKindSlidesDate
Technical Presentation (August 2024)Technical9 slidesAugust 2024
Conference Presentation (August 2024)Conference29 slidesAugust 2024
ARCH 2-Year Topline Results Investor Call (April 2024)Conference36 slidesApr 16, 2024
American Academy of Neurology (AAN) 2024Conference14 slidesApr 16, 2024
28th International Annual Congress of the World Muscle Society 2023Conference59 slidesOct 3, 2023
PPMD Annual Conference 2023Conference22 slidesJune 2023
PPMD Annual Conference 2023Conference10 slidesJune 2023
Investor Day (January 2023)Investor day76 slidesJan 3, 2023
2023 HCMS Scientific SessionsConference9 slides2023
27th International Annual Congress of the World Muscle Society 2022Conference98 slidesOct 14, 2022
PPMD Connect Conference 2022Conference15 slides2022
New Directions in Biology and Disease of Skeletal Muscle Conference 2021Conference26 slidesJun 28, 2021
PPMD Connect Conference 2021Conference8 slidesJune 2021

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$200M · US$20.13 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead)
Buyers: Braidwell LP; Cormorant Asset Management; Driehaus Capital Management; Invus; Janus Henderson Investors; MPM BioImpact; OrbiMed; Paradigm BioCapital Advisors; Perceptive Advisors; RA Capital Management; Sofinnova Investments, Inc.
Use of proceeds: Potential US launch of sevasemten in Becker, Phase 3 trials of sevasemten and EDG-7500, other R&D, working capital and general corporate purposes
Apr 2, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Mar 25, 2021.

Price
US$16.00 a share
Shares offered
11,000,000 shares of common stock
Offering size
US$176 million
Underwriters' option
Up to 1,650,000 more shares
Listing
EWTX on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Goldman Sachs & Co. LLC, SVB Leerink, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Mar 30, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceDec 18, 2020
Filed publiclyMar 5, 2021
Amended twiceNewest Mar 24, 2021
Shares registered with an exchangeMar 17, 2021
Declared effective by the SECMar 25, 2021
Final prospectus, with the priceMar 26, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Mar 26, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue2.27M2.29M1.73M538.0K272.0K185.0K123.0K
Gross profit-2.27M-2.29M-1.73M-538.0K-272.0K-185.0K-123.0K
Research and development151.4M127.0M90.9M54.0M32.2M15.0M8.62M
Selling, general and administrative40.0M31.9M23.5M5.47M11.0M2.21M1.30M
Operating income-191.4M-158.8M-114.4M-71.7M-43.2M-17.2M-9.92M
Depreciation and amortization2.08M2.07M1.55M368.0K272.0K185.0K123.0K
EBITDA-189.3M-156.8M-112.8M-71.3M-42.9M-17.0M-9.80M
Interest expense4.02M272.0K69.0K0
Income before tax-167.8M-133.8M-100.2M-19.4M-42.8M-17.1M-9.71M
Income tax4.00K3.00K4.00K00-69.0K-219.0K
Net income-167.8M-133.8M-100.2M-67.6M-42.8M-17.1M-9.49M
Earnings per share, basic-1.63-1.45-1.57-1.26-1.14-23.17-0.19
Earnings per share, diluted-1.63-1.45-1.57-1.26-1.14-23.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents61.1M41.7M86.1M22.0M15.6M104.9M23.7M
Short-term investments469.0M428.5M232.3M330.0M265.2M24.2M0
Receivables251.0K548.0K
Current assets543.4M475.5M327.0M357.0M283.8M129.6M24.0M
Property, plant and equipment7.83M9.50M10.4M8.53M912.0K516.0K498.0K
Total assets552.6M486.8M340.0M367.1M285.2M131.1M24.5M
Accounts payable6.01M5.58M4.03M6.11M3.84M1.58M667.0K
Current liabilities27.4M23.9M16.8M16.6M10.5M4.34M1.13M
Total debt3.99M4.74M5.41M4.41M160.2M40.3M
Total liabilities30.3M27.6M21.2M20.4M10.8M4.34M41.4M
Shareholders' equity522.3M459.2M318.8M346.7M274.4M-33.4M-16.9M
Shares outstanding106.2M94.8M70.5M63.3M49.5M1.01M49.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-143.8M-109.0M-91.9M-52.6M-33.5M-14.6M-9.17M
Capital spending-256.0K-1.31M-5.75M-5.55M-668.0K-203.0K-180.0K
Free cash flow-144.1M-110.3M-97.7M-58.2M-34.2M-14.8M-9.35M
Cash from investing-32.8M-184.7M102.9M-70.6M-242.2M-24.4M-180.0K
Cash from financing196.1M249.3M53.2M129.6M186.4M120.3M24.8M
Share buybacks129.9M186.4M
Change in cash19.5M-44.4M64.1M6.43M-89.3M81.3M15.4M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
8-K · Current reportNov 4, 2026ResultsSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 17, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 17, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4/A · Change in ownership, amendedAug 17, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 17, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
8-K/A · Current report, amendedJul 16, 2026Current reportSEC
8-K · Current reportJul 13, 2026Acquisition or disposalSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
8-K · Current reportJun 5, 2026Meeting outcomeSEC
8-K · Current reportJun 1, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 7, 2026Offer documentSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
144 · Notice of proposed saleMar 27, 2026Other filingsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
144 · Notice of proposed saleJan 21, 2026Other filingsSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 24, 2025Insider tradeSEC
8-K · Current reportNov 20, 2025Management or board changeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
8-K · Current reportNov 10, 2025Management or board changeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
144 · Notice of proposed saleAug 26, 2025Other filingsSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Current reportSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialMay 14, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
424B5 · ProspectusApr 2, 2025Offer documentSEC
8-K · Current reportApr 2, 2025Material contractSEC
8-K · Current reportApr 2, 2025Current reportSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 3, 2025Offer documentSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
8-K · Current reportMar 3, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 21, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 3, 2025Big-stake noticeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
144 · Notice of proposed saleJan 28, 2025Other filingsSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 23, 2025Insider tradeSEC
8-K · Current reportJan 22, 2025Management or board changeSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
144 · Notice of proposed saleDec 30, 2024Other filingsSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
144 · Notice of proposed saleDec 26, 2024Other filingsSEC
8-K · Current reportDec 16, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 7, 2024Offer documentSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedSep 23, 2024Big-stake noticeSEC
144 · Notice of proposed saleSep 23, 2024Other filingsSEC
144 · Notice of proposed saleSep 20, 2024Other filingsSEC
144 · Notice of proposed saleSep 20, 2024Other filingsSEC
144 · Notice of proposed saleSep 20, 2024Other filingsSEC
144 · Notice of proposed saleSep 20, 2024Other filingsSEC
144 · Notice of proposed saleSep 20, 2024Other filingsSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
8-K · Current reportAug 12, 2024Management or board changeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
8-K · Current reportJun 10, 2024Meeting outcomeSEC
8-K · Current reportMay 10, 2024Material contractSEC
S-3ASR · Registration statementMay 10, 2024Offer documentSEC
S-8 · Registration statement for employee plansMay 9, 2024Offer documentSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
4 · Change in ownershipMay 7, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2024Insider tradeSEC
DEFA14A · Additional proxy materialMay 7, 2024Meeting noticeSEC
8-K · Current reportMay 7, 2024Management or board changeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC

This page holds 200 of 426 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Edgewise Therapeutics, Inc.’s releases · as of Oct 31, 2026

Common shares
109,482,763
Fully diluted
109,482,763

Fully diluted

LineSharesAs of
Common shares109,482,763Oct 31, 2026

Share count over time

CountShares
Oct 31, 2026109,482,763

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Orbimed Advisors LLC15.5MUS$630MSep 30, 2026
Paradigm Biocapital Advisors LP10.8MUS$438MSep 30, 2026
Ra Capital Management, L.P.8.39MUS$341MSep 30, 2026
Janus Henderson7.3MUS$296MSep 30, 2026
BlackRock7.27MUS$295MSep 30, 2026
Vanguard5.39MUS$219MSep 30, 2026
Novo Holdings A/S5.35MUS$217MSep 30, 2026
Driehaus Capital Management LLC4.4MUS$179MSep 30, 2026
Perceptive Advisors LLC4.14MUS$168MSep 30, 2026
Baker Bros. Advisors LP3.7MUS$150MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Siren, L.L.C.2.8MUS$114MSep 30, 2026
Bank of America2.59MUS$105MSep 30, 2026
Citadel2.57MUS$104MSep 30, 2026
First Light Asset Management, LLC2.48MUS$101MSep 30, 2026
Integral Health Asset Management, LLC2.4MUS$97.4MSep 30, 2026
Geode Capital2.28MUS$92.7MSep 30, 2026
Braidwell LP2.07MUS$84MSep 30, 2026
State Street1.9MUS$77.1MSep 30, 2026
Cormorant Asset Management, LP1.86MUS$75.5MSep 30, 2026
Morgan Stanley1.74MUS$70.7MSep 30, 2026
AllianceBernstein1.73MUS$70.3MSep 30, 2026
Mpm Bioimpact LLC1.58MUS$64MSep 30, 2026
Marshall Wace, LLP1.26MUS$51MSep 30, 2026
Deep Track Capital, LP1.15MUS$46.6MSep 30, 2026
American Century1.13MUS$45.8MSep 30, 2026
Adage Capital Partners Gp, L.L.C.990KUS$40.2MSep 30, 2026
Fidelity971KUS$39.4MSep 30, 2026
Balyasny Asset Management L.P.949KUS$38.5MSep 30, 2026
Qube Research & Technologies Ltd914KUS$37.1MSep 30, 2026
Victory Capital904KUS$36.7MSep 30, 2026
Goldman Sachs817KUS$33.2MSep 30, 2026
T. Rowe Price774KUS$31.4MSep 30, 2026
Assenagon Asset Management S.A.735KUS$29.8MSep 30, 2026
Schwab704KUS$28.6MSep 30, 2026
Susquehanna692KUS$28.1MSep 30, 2026
Northern Trust685KUS$27.8MSep 30, 2026
Tyro Capital Management LLC662KUS$26.9MSep 30, 2026
Pictet Asset Management Holding SA662KUS$26.9MSep 30, 2026
Dimensional613KUS$24.9MSep 30, 2026
Squadron Capital Management LLC425KUS$17.3MSep 30, 2026
Nuveen422KUS$17.1MSep 30, 2026
abrdn413KUS$16.8MSep 30, 2026
Sofinnova Investments, Inc.397KUS$16.1MSep 30, 2026
Soleus Capital Management, L.P.330KUS$13.4MSep 30, 2026
Artisan Partners Limited Partnership329KUS$13.4MSep 30, 2026
Parkman Healthcare Partners LLC328KUS$13.3MSep 30, 2026
Raymond James Financial Inc302KUS$12.3MSep 30, 2026
Universal- Beteiligungs- und Servicegesellschaft mbH292KUS$11.8MSep 30, 2026
DWS275KUS$11.2MSep 30, 2026
Casdin Capital, LLC265KUS$10.8MSep 30, 2026

This page holds 50 of 244 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund2.9MUS$118MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.94MUS$66.3MMay 31, 2026
iShares Russell 2000 ETF1.84MUS$74.6MJun 30, 2026
Vanguard Extended Market Index Fund865KUS$35.1MJun 30, 2026
Small Cap Growth Fund856KUS$32.9MJul 31, 2026
Victory Pioneer Select Mid Cap Growth Fund796KUS$27.2MMay 31, 2026
Fidelity Small Cap Index Fund782KUS$30.1MJul 31, 2026
Select Biotechnology Portfolio699KUS$23.9MMay 31, 2026
Janus Henderson Global Life Sciences Fund677KUS$27.5MJun 30, 2026
iShares Russell 2000 Growth ETF660KUS$26.8MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Small Cap Growth Fund643KUS$24.7MJul 31, 2026
iShares Biotechnology ETF556KUS$22.6MJun 30, 2026
AB Small Cap Growth Portfolio534KUS$21.7MJun 30, 2026
Driehaus Small Cap Growth Fund522KUS$21.2MJun 30, 2026
AB Discovery Growth Fund, Inc.490KUS$19.9MJun 30, 2026
Janus Henderson Triton Fund471KUS$19.2MJun 30, 2026
Fidelity Extended Market Index Fund383KUS$13.1MMay 31, 2026
Schwab U.S. Small-Cap ETF355KUS$12.1MMay 31, 2026
Vanguard Russell 2000 Index Fund347KUS$11.8MMay 31, 2026
Fidelity Small Cap Growth K6 Fund329KUS$12.7MJul 31, 2026
Artisan International Small-Mid Fund329KUS$13.4MJun 30, 2026
Janus Henderson Venture Fund312KUS$12.7MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund300KUS$12.2MJun 30, 2026
Select Health Care Portfolio294KUS$10MMay 31, 2026
U.S. Small Cap Portfolio269KUS$10.3MJul 31, 2026
U.S. Micro Cap Portfolio259KUS$9.97MJul 31, 2026
T. Rowe Price New Horizons Fund, Inc.234KUS$9.49MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF226KUS$9.2MJun 30, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund226KUS$8.7MJul 31, 2026
EQ/AB Small Cap Growth Portfolio212KUS$8.62MJun 30, 2026
Driehaus Micro Cap Growth Fund207KUS$8.39MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF199KUS$8.07MJun 30, 2026
iShares U.S. Pharmaceuticals ETF196KUS$7.96MJun 30, 2026
SmallCap Growth Fund I174KUS$6.68MJul 31, 2026
Schwab Small-Cap Index Fund174KUS$6.68MJul 31, 2026
Dimensional U.S. Small Cap ETF169KUS$6.49MJul 31, 2026
Vanguard Health Care Index Fund159KUS$5.43MMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account147KUS$5.96MJun 30, 2026
Fidelity Advisor Biotechnology Fund145KUS$5.55MJul 31, 2026
Fidelity Advisor Health Care Fund143KUS$5.5MJul 31, 2026
Fidelity Total Market Index Fund139KUS$4.74MMay 31, 2026
Column Small Cap Select Fund139KUS$4.73MMay 31, 2026
Master Small Cap Index Series131KUS$5.32MJun 30, 2026
AST Small-Cap Equity Portfolio131KUS$5.31MJun 30, 2026
JNL Multi-Manager Small Cap Growth Fund128KUS$5.19MJun 30, 2026
Fidelity Series Total Market Index Fund113KUS$3.85MMay 31, 2026
ALPS Medical Breakthroughs ETF111KUS$3.78MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF105KUS$4.27MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF104KUS$3.98MJul 31, 2026
Neuberger Small Cap Growth Fund96,570US$3.3MMay 31, 2026

This page holds 50 of 224 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Donovan Joanne M.
Officer: CMO
Sale854USD 45.48US$38,840Nov 16, 2026
Nofi Michael
Officer: Chief Financial Officer
Sale4,442USD 45.43US$202KNov 10, 2026
Donovan Joanne M.
Officer: CMO
Sale2,919USD 43.41US$127KAug 13, 2026
Koch Kevin
Director, Officer: President and CEO
Sale8,782USD 43.64US$383KAug 12, 2026
Koch Kevin
Director, Officer: President and CEO
Sale8,276USD 43.66US$361KAug 12, 2026
Koch Kevin
Director, Officer: President and CEO
Sale913USD 44.33US$40,473Aug 12, 2026
Moore John R
Officer: General Counsel
Sale2,439USD 43.81US$107KAug 12, 2026
Moore John R
Officer: General Counsel
Sale59USD 44.41US$2,620Aug 12, 2026
Moore John R
Officer: General Counsel
Sale99USD 44.50US$4,406Aug 12, 2026
Moore John R
Officer: General Counsel
Sale2,419USD 43.80US$106KAug 12, 2026
All 26 trades
TradeTradeSharesPriceValueDate
Donovan Joanne M.
Officer: CMO
Sale2,839USD 43.78US$124KAug 12, 2026
Donovan Joanne M.
Officer: CMO
Sale2,779USD 43.71US$121KAug 12, 2026
Donovan Joanne M.
Officer: CMO
Sale104USD 44.43US$4,621Aug 12, 2026
Donovan Joanne M.
Officer: CMO
Sale800USD 44.52US$35,616Aug 12, 2026
Derakhshan Behrad
Officer: Chief Business Officer
Sale2,171USD 43.79US$95,068Aug 12, 2026
Derakhshan Behrad
Officer: Chief Business Officer
Sale304USD 44.50US$13,528Aug 12, 2026
Derakhshan Behrad
Officer: Chief Business Officer
Sale150USD 44.44US$6,666Aug 12, 2026
Derakhshan Behrad
Officer: Chief Business Officer
Sale2,475USD 43.70US$108KAug 12, 2026
Russell Alan J
Director, Officer: Chief Scientific Officer
Sale3,238USD 43.68US$141KAug 12, 2026
Russell Alan J
Director, Officer: Chief Scientific Officer
Sale2,273USD 43.68US$99,285Aug 12, 2026
Russell Alan J
Director, Officer: Chief Scientific Officer
Sale390USD 44.46US$17,339Aug 12, 2026
Russell Alan J
Director, Officer: Chief Scientific Officer
Sale130,352USD 39.41US$5.14MJul 1, 2026
Russell Alan J
Director, Officer: Chief Scientific Officer
Sale69,648USD 39.41US$2.74MJul 1, 2026
Donovan Joanne M.
Officer: CMO
Sale50,000USD 38.57US$1.93MMay 5, 2026
Donovan Joanne M.
Officer: CMO
Sale5,230USD 31.29US$164KMay 4, 2026
Donovan Joanne M.
Officer: CMO
Sale28,662USD 32.31US$926KApr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Orbimed Advisors LLC14.50%15.3MMay 9, 2025Schedule 13D
Paradigm Biocapital Advisors LP9.50%10.2MJun 30, 2026Schedule 13G
Ra Capital Management, L.P.7.80%8.39MJun 30, 2026Schedule 13G
Janus Henderson Group PLC6.70%7.3MSep 30, 2026Schedule 13G
BlackRock, Inc.5.50%5.82MJun 30, 2025Schedule 13G
Novo Holdings A/S4.90%5.35MApr 23, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Laura Brege
Other companies: Mirum Pharmaceuticals, Inc. (Board Member · Since at least Jul 17, 2019); ACADIA Pharmaceuticals Inc. (Director · Since at least Jun 10, 2016); Pacira BioSciences, Inc. (Director · Since at least Jun 6, 2016); Aratana Therapeutics Inc (Director · Jun 24, 2016 – Jul 27, 2018 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Dynavax Technologies Corporation (Director · May 31, 2016 – May 30, 2019 · Past)
Director · Since at least Mar 25, 2021
Arlene Morris
Other companies: Palatin Technologies, Inc. (Director · Since at least Jun 22, 2022); Viridian Therapeutics, Inc. (Chief Executive Officer, Willow Advisors · Since at least Jun 8, 2022); Cogent Biosciences, Inc. (Director · Since at least Jun 7, 2022); Viveve Medical, Inc. (Director · Jan 3, 2023 – Jan 3, 2023 · Past)
Director · Since at least May 6, 2024
Jonathan Root
Other companies: Carlsmed, Inc. (Director · Since at least Jul 22, 2025); Omada Health, Inc. (Director · Since at least Jun 5, 2025)
Director · Since at least Jun 16, 2025
Marc Semigran
Other companies: ProKidney Corp. (Director · Jun 29, 2021 – Jun 29, 2021 · Past); MyoKardia Inc (Chief Medical Officer · Dec 1, 2016 – Feb 8, 2019 · Past)
Chief Development Officer · Dec 19, 2022 – Dec 24, 2024 · Past
Badreddin Edris
Other companies: SpringWorks Therapeutics Inc (Chief Operating Officer · Since at least Jan 4, 2024)
Director and Co-Founder · Since at least Jun 10, 2024
Kevin Koch
Other companies: Viridian Therapeutics, Inc. (Director · Jun 27, 2018 – May 21, 2020 · Past)
Director · Since at least Mar 25, 2021
Alan RussellDirector and Co-Founder · Since at least May 1, 2025
Behrad DerakhshanChief Operating Officer · Since at least May 1, 2025
Christopher MartinDirector · Since at least Nov 20, 2025
Joanne M. DonovanChief Medical Officer · Since at least Mar 10, 2026
All 15 people
PersonSeat
John MooreGeneral Counsel · Since at least Aug 14, 2026
Jonathan C. FoxDirector · Since at least Oct 2, 2026
Jon RootDirector · Since at least Nov 4, 2026
Michael NofiChief Financial Officer · Since at least Nov 10, 2025
Peter ThompsonChairman and Co-Founder · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Edgewise Therapeutics, Inc.